Companies › Shanghai Fosun Pharmaceutical Industrial Development
9 active drug programs in 12 registered trials: 5 Phase 2, 5 Phase 1, 2 Phase 3; Oncology, Respiratory, Infectious disease, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FCN-159 | – | Phase 3 | Neurofibromatosis 1; Langerhans Cell Histiocytosis | May 2027 |
| Foritinib Succinate (SAF-189s) ALK inhibitor | ALK | Phase 3 | Non-Small Cell Lung Cancer | Dec 2027 |
| XH-S004 | – | Phase 2 | Non-Cystic Fibrosis Bronchiectasis; Chronic Obstructive Pulmonary Disease | Nov 2026 |
| FCN-338 | – | Phase 2 | Safety | Dec 2026 |
| FXS5626 | – | Phase 2 | Active Non-anterior, Non-infectious Uveitis; Evaluation of QTc Interval | Jan 2027 |
| luvometinib MEK1/2 inhibitor | MAP2K1 | Phase 2 | Non-small Cell Lung Caner | Jun 2029 |
| XS-04 | – | Phase 1 | B-cell Lymphoma | Nov 2027 |
| FXS0683 BCL-2 inhibitor | BCL2 | Phase 1 | B-Cell Lymphoma | Aug 2028 |
| XS-02 | – | Phase 1 | Solid Tumor | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05913037 | FCN-159 | Phase 3 | Neurofibromatosis 1 | Oncology | Aug 2025 |
| NCT07035652 | XH-S004 | Phase 1 | Chronic Obstructive Pulmonary Disease | Respiratory | Nov 2026 |
| NCT06858618 | FCN-338 | Phase 2 | Safety | Oncology | Dec 2026 |
| NCT06981091 | XH-S004 | Phase 2 | Non-Cystic Fibrosis Bronchiectasis | Respiratory | Jan 2027 |
| NCT07695779 | FXS5626 | Phase 1 | Evaluation of QTc Interval | Other | Jan 2027 |
| NCT07552012 | FXS5626 | Phase 2 | Active Non-anterior, Non-infectious Uveitis | Infectious disease | Feb 2027 |
| NCT05997602 | FCN-159 | Phase 2 | Langerhans Cell Histiocytosis | Oncology | May 2027 |
| NCT06820268 | XS-04 | Phase 1 | B-cell Lymphoma | Oncology | Nov 2027 |
| NCT06569420 | Foritinib Succinate (SAF-189s) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07616089 | FXS0683 | Phase 1 | B-Cell Lymphoma | Oncology | Aug 2028 |
| NCT06531486 | XS-02 | Phase 1 | Solid Tumor | Oncology | May 2029 |
| NCT07562581 | luvometinib | Phase 2 | Non-small Cell Lung Caner | Oncology | Jun 2029 |
Ascentage Pharma Group Roche Pfizer AbbVie BeOne Medicines Novartis Bio-Path Holdings BeiGene Lomond Therapeutics Holdings Guangzhou Lupeng Pharmaceutical Company
Shenzhen TargetRx Pierre Fabre Medicament Shanghai Kechow Pharma CStone Pharmaceuticals CSPC Megalith Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.